Market Place
Sourcing Support
Getting patented meds on NLEM list an uphill battle says committee member
15 Sep 2022 //
ECONOMIC TIMES
AbbVie inks licensing deal to boost Mavyret access in nearly 100 countries
14 Nov 2018 //
FIERCE PHARMA
Natco Pharma launches Hepatitis C drug in India
03 Jul 2018 //
ECONOMIC TIMES
Epclusa`s fast-tracked Chinese approval might be late for Gilead
31 May 2018 //
FIERCE PHARMA
Opdivo, Repatha and Lynparza likely among China’s 2018 blockbuster nods: report
06 Jan 2018 //
FIERCE PHARMA
EU Health Regulator Warns Some Hep C Drugs Could Reactivate Hep B
03 Dec 2016 //
REUTERS
Mylan Signs Sub-license Agreement with the Medicines Patent Pool
28 Nov 2016 //
PR NEWSWIRE
Recent Success in HCV Treatment Brings Relief to Patients
07 Nov 2016 //
DRUG DEVELOPMENT
New Hep C drugs grow in low-middle income countries
28 Oct 2016 //
PHARMA TIMES
Japan`s PMDA reviews hep B risk link to hep C therapies
04 May 2016 //
FIERCE ASIA
EU extends safety review of chronic Hep C treatments
15 Apr 2016 //
REUTERS
Is This the Company Gilead Sciences Should Fear Most?
22 Feb 2016 //
MOTLEY FOOL
BMS PhIII hep C combo results a milestone for China plans
22 Feb 2016 //
FIERCE PHARMA ASIA
Regulus hep C combo drug effective in mid-stage study
18 Feb 2016 //
REUTERS
Gilead nabs two new Harvoni approvals as hep C contest heats up
17 Feb 2016 //
FIERCE PHARMA
Medicines Patent Pool Signs First Sub-licences for Hep C Medicine Daclatasvir
21 Jan 2016 //
PR NEWSWIRE
Cipla to sell hepatitis C drug Daclatasvir
20 Jan 2016 //
BUSINESS STANDARD
Desi generics firms pave way for cheaper hepatitis C drug
18 Jan 2016 //
ECONOMIC TIMES
Torrent launches world`s second biosimilar of generic auto-immune drug
11 Jan 2016 //
BUSINESS STANDARD
First-of-a-kind drug approvals continued rise in 2015
05 Jan 2016 //
ET HEALTHWORLD
Australia bets $1B on pricey hepC drug in broad effort to eradicate the disease
23 Dec 2015 //
FIERCE PHARMA
Shift in law helps local pharma groups in the Philippines
21 Dec 2015 //
ABC NEWS
Natco Pharma gets DCGI nod to sell hepatitis C treatment drug
14 Dec 2015 //
ECONOMIC TIMES
Hetero receives drug controller approval for generic Daclatasvir
14 Dec 2015 //
ECONOMIC TIMES
Hepatitis C cure may cost as low as Rs 67,000
30 Nov 2015 //
ECONOMIC TIMES
Hep C patients to get NHS access to three new therapies
26 Nov 2015 //
PHARMATIMES
BMS gets a leg in the China hep C race with PhI for Daklinza
19 Nov 2015 //
FIERCE PHARMA ASIA
Gilead`s Sovaldi Tied to Slow Heartbeat in Hepatitis C Patients
05 Nov 2015 //
BLOOMBERG
Indian drugmakers take page from HIV playbook for hep C combo pill
09 Oct 2015 //
FIERCE PHARMA ASIA
BMS gets speedy US review for Daklinza applications
06 Oct 2015 //
PHARMATIMES
FDA grants priority review for HCV treatment Daklinza sNDAs
06 Oct 2015 //
EUROPEAN PHRMACEUTICAL
Anvisa approves expansion of use for the drug Daklinza
10 Sep 2015 //
ANVISA
EU OKs shorter, ribavirin-free Daklinza regimen for HCV
10 Sep 2015 //
PHARMATIMES
Access to new hep C treatments put under the spotlight
29 Jul 2015 //
PM LIVE
WHO Adds Gilead Hepatitis C Drugs to its List of Essential Medicines
09 May 2015 //
THE WALL STREET JOURNAL
Caforio takes CEO role as BMS faces tough year with promising new drugs
07 May 2015 //
FIERCE PHARMA MARKETING
From the pharma C-suite: Notable, quotable remarks on Asia, emerging markets for Q1 (Part 5)
05 May 2015 //
FIERCE PHARMA ASIA
BMS` Opdivo backed as melanoma therapy in EU
27 Apr 2015 //
PM LIVE
AbbVie moves closer to Japan`s crowded hep C field with priority review nod
17 Apr 2015 //
FIERCE PHARMA
Japan pharma market on track for $80B mark by 2020, but obstacles seen
01 Apr 2015 //
FIERCE PHARMA ASIA
